

FLEXIBLE STRENGTH. PROVEN SUCCESS.

Proven procedural success and durable clinical outcomes through 3 years


Proven procedural success:

- 100% restoration of lumen diameter¹
- 100% delivery to target lesion with no device dislodgement¹
- 96.9% primary patency at nine months¹

Sustained clinical effectiveness through 3 years:

- 91.2% freedom from target lesion revascularization (fTLR)²

The Gore VBX FLEX Clinical Study is a prospective, multicenter, single-arm study of 134 patients with complex aortoiliac occlusive disease (32.1% TASC II C and D, 42.5% kissing stent)



Kaplan-Meier graph of fTLR per lesion with number of lesions at risk

DURABLE PATIENT BENEFIT VERSUS BASELINE THROUGH 3 YEARS²

92% of patients with improvement
in Rutherford category²

.17 improvement in mean resting ankle-brachial
index (ABI) ($P < .001$, .93 mean ABI)^{*,2}

2-3x improvement in median WIQ measures[†]

	Pre-procedure	9 months	2 years	3 years
Walking distance	8 (N = 134)	22 (N = 114)	22 (N = 104)	22 (N = 90)
Walking speed	3 (N = 134)	11 (N = 114)	10 (N = 104)	10 (N = 90)
Stair climbing	4 (N = 127)	9 (N = 114)	9 (N = 102)	9 (N = 87)

* ($P < .001$) Statistically significant change from pre-procedure.

† Data on file 2020; W. L. Gore & Associates, Inc.; Flagstaff, AZ.

References

1. Bismuth J, Gray BH, Holden A, Metzger C, Panneton J; VBX FLEX Study Investigators. Pivotal study of a next-generation balloon-expandable stent-graft for treatment of iliac occlusive disease. *Journal of Endovascular Therapy* 2017;24(5):629-637. <http://journals.sagepub.com/doi/full/10.1177/1526602817720463>.
2. Panneton JM, Bismuth J, Gray BH, Holden A. Three-year follow-up of patients with iliac occlusive disease treated with the Viabahn Balloon-Expandable Endoprosthesis. *Journal of Endovascular Therapy*. In press. <https://journals.sagepub.com/doi/10.1177/1526602820920569>

INDICATIONS FOR USE IN THE U.S., AUSTRALIA, NEW ZEALAND, CANADA AND LATIN AMERICA: The GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis is indicated for the treatment of de novo or restenotic lesions found in iliac arteries with reference vessel diameters ranging from 5 mm - 13 mm and lesion lengths up to 110 mm, including lesions at the aortic bifurcation. **CONTRAINDICATIONS:** Do not use the GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis in patients with known hypersensitivity to heparin, including those patients who have had a previous incident of Heparin-Induced Thrombocytopenia (HIT) type II. Refer to *Instructions for Use* at eifu.goremedical.com for a complete description of all applicable indications, warnings, precautions and contraindications for the markets where this product is available. ^{Rx only}

 Consult Instructions
for Use
eifu.goremedical.com

Products listed may not be available in all markets.

GORE, *Together, improving life*, VBX, VBX FLEX, VIABAHN and designs are trademarks of W. L. Gore & Associates. © 2020 W. L. Gore & Associates, Inc. AY1087-EN2 MAY 2020

W. L. Gore & Associates, Inc.
goremedical.com

Asia Pacific +65 67332882 Australia / New Zealand 1800 680 424 Europe 00800 6334 4673
United States Flagstaff, AZ 86003 800 437 8181 928 779 2771

